Human medicines European public assessment report (EPAR): Imatinib medac, imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma,Dermatofibrosarcoma,Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Myelodysplastic-Myeloproliferative Diseases,Hypereosinophilic Syndrome, Date of authorisation: 25/09/2013, Revision: 5, Status: Withdrawn

Case Medical Research ◽

10.31525/cmr-1f67616 ◽

2019 ◽

Author(s):

Keyword(s):

Lymphoblastic Leukemia ◽

Hypereosinophilic Syndrome ◽

Precursor Cell ◽

Assessment Report ◽

European Public ◽

Myeloproliferative Diseases ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Glivec, imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma,Gastrointestinal Stromal Tumors,Dermatofibrosarcoma,Myelodysplastic-Myeloproliferative Diseases,Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Hypereosinophilic Syndrome, Date of authorisation: 07/11/2001, Revision: 35, Status: Authorised

Case Medical Research ◽

10.31525/cmr-106e822 ◽

2019 ◽

Author(s):

Keyword(s):

Gastrointestinal Stromal Tumors ◽

Lymphoblastic Leukemia ◽

Hypereosinophilic Syndrome ◽

Precursor Cell ◽

Assessment Report ◽

Stromal Tumors ◽

European Public ◽

Myeloproliferative Diseases ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Imatinib Accord, imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma,Dermatofibrosarcoma,Myelodysplastic-Myeloproliferative Diseases,Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Hypereosinophilic Syndrome, Date of authorisation: 30/06/2013, Revision: 14, Status: Authorised

Case Medical Research ◽

10.31525/cmr-399646 ◽

2019 ◽

Author(s):

Keyword(s):

Lymphoblastic Leukemia ◽

Hypereosinophilic Syndrome ◽

Precursor Cell ◽

Assessment Report ◽

European Public ◽

Myeloproliferative Diseases ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Imatinib Teva, imatinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Myelodysplastic-Myeloproliferative Diseases,Hypereosinophilic Syndrome,Dermatofibrosarcoma, Date of authorisation: 07/01/2013, Revision: 12, Status: Authorised

Case Medical Research ◽

10.31525/cmr-57f58c ◽

2018 ◽

Author(s):

Keyword(s):

Lymphoblastic Leukemia ◽

Hypereosinophilic Syndrome ◽

Precursor Cell ◽

Assessment Report ◽

European Public ◽

Myeloproliferative Diseases ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Imatinib Actavis, imatinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Myelodysplastic-Myeloproliferative Diseases,Hypereosinophilic Syndrome,Dermatofibrosarcoma, Date of authorisation: 17/04/2013, Revision: 11, Status: Authorised

Case Medical Research ◽

10.31525/cmr-9e7b77 ◽

2019 ◽

Author(s):

Keyword(s):

Lymphoblastic Leukemia ◽

Hypereosinophilic Syndrome ◽

Precursor Cell ◽

Assessment Report ◽

European Public ◽

Myeloproliferative Diseases ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Glivec, imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma,Gastrointestinal Stromal Tumors,Dermatofibrosarcoma,Myelodysplastic-Myeloproliferative Diseases,Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Hypereosinophilic Syndrome, Date of authorisation: 07/11/2001, Revision: 34, Status: Authorised

Case Medical Research ◽

10.31525/cmr-105ef9f ◽

2019 ◽

Author(s):

Keyword(s):

Gastrointestinal Stromal Tumors ◽

Lymphoblastic Leukemia ◽

Hypereosinophilic Syndrome ◽

Precursor Cell ◽

Assessment Report ◽

Stromal Tumors ◽

European Public ◽

Myeloproliferative Diseases ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Imatinib Teva, imatinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Myelodysplastic-Myeloproliferative Diseases,Hypereosinophilic Syndrome,Dermatofibrosarcoma, Date of authorisation: 07/01/2013, Revision: 13, Status: Authorised

Case Medical Research ◽

10.31525/cmr-58723d ◽

2019 ◽

Author(s):

Keyword(s):

Lymphoblastic Leukemia ◽

Hypereosinophilic Syndrome ◽

Precursor Cell ◽

Assessment Report ◽

European Public ◽

Myeloproliferative Diseases ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Imatinib Accord, imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma,Dermatofibrosarcoma,Myelodysplastic-Myeloproliferative Diseases,Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Hypereosinophilic Syndrome, Date of authorisation: 30/06/2013, Revision: 15, Status: Authorised

Case Medical Research ◽

10.31525/cmr-587203 ◽

2019 ◽

Author(s):

Keyword(s):

Lymphoblastic Leukemia ◽

Hypereosinophilic Syndrome ◽

Precursor Cell ◽

Assessment Report ◽

European Public ◽

Myeloproliferative Diseases ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Imatinib Actavis, imatinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Myelodysplastic-Myeloproliferative Diseases,Hypereosinophilic Syndrome,Dermatofibrosarcoma, Date of authorisation: 17/04/2013, Revision: 12, Status: Authorised

Case Medical Research ◽

10.31525/cmr-9e21cb ◽

2019 ◽

Author(s):

Keyword(s):

Lymphoblastic Leukemia ◽

Hypereosinophilic Syndrome ◽

Precursor Cell ◽

Assessment Report ◽

European Public ◽

Myeloproliferative Diseases ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Jylamvo, methotrexate, Arthritis, Psoriatic,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Psoriasis,Arthritis, Rheumatoid,Arthritis, Date of authorisation: 29/03/2017, Revision: 4, Status: Authorised

Case Medical Research ◽

10.31525/cmr-f38737 ◽

2019 ◽

Author(s):

Keyword(s):

Rheumatoid Arthritis ◽

Lymphoblastic Leukemia ◽

Precursor Cell ◽

Assessment Report ◽

Psoriasis Arthritis ◽

European Public ◽

European Public Assessment Report ◽

Arthritis Rheumatoid

Download Full-text

Human medicines European public assessment report (EPAR): Sprycel, dasatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma,Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Date of authorisation: 20/11/2006, Revision: 32, Status: Authorised

Case Medical Research ◽

10.31525/cmr-ed3b4f ◽

2019 ◽

Author(s):

Keyword(s):

Lymphoblastic Leukemia ◽

Precursor Cell ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text